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GermanyS1. CELL SIGNALING BY RECEPTOR TYROSINE KINASES:
FROM BASIC CONCEPTS TO CLINICAL APPLICATIONS
Joseph Schlessinger. Yale University School of Medicine, Department
of Pharmacology, P.O. Box 208066 New Haven, CT 06520, USA.
Receptor tyrosine kinases (RTKs) comprise a large family of cell
surface receptors that control many critical cellular processes.
The intrinsic protein kinase activity of RTKs is stimulated follow-
ing growth factor binding to the extracellular ligand-binding
domain which stimulates receptor dimerization, tyrosine auto-
phosphorylation and enhancement of enzymatic activity leading
to the recruitment and activation of multiple intracellular signal-
ing pathways. It is now well established that various human dis-
eases and pathologies are caused by dysfunction in RTKs or in the
intracellular signaling pathways that they activate. These include
many cancers, developmental abnormalities, sever bone disor-
ders, immune diseases, arteriosclerosis and angiogenesis among
others.
We have used mass spectrometry and X-ray crystallography to
demonstrate that tyrosine autophosphorylation of the catalytic
tyrosine kinase domain of FGF-receptor-1 (FGFR1) is mediated
by a sequential and precisely ordered reaction. We also demon-
strate that the rate of catalysis of two FGFR substrates is
enhanced by 50–100-fold following autophosphorylation of the
first site in the activation loop while autophosphorylation of the
second site in the activation loop results in 500–1000-fold increase
in the rate of substrate phosphorylation. We propose that FGFR1
is activated by a two-step mechanism mediated by strictly
ordered and regulated autophosphorylation suggesting that dis-
tinct phosphorylation states may provide both temporal and spa-
tial resolution to receptor signaling. Genetic models in mice
provide new opportunities for exploring and developing new
treatments for diseases caused by dysfunctions in RTKs and in
their intracellular signaling pathways. Inhibitors of tyrosine
kinases have been successfully applied for the treatment of can-
cers driven by activated tyrosine kinases. Sutent/SU11248 is a
new drug that blocks the actions of several tyrosine kinasesdoi:10.1016/j.ejcsup.2006.04.001including c-Kit, PDGFR and VEGFR. Sutent has been approved by
the FDA for the treatment of gastrointestinal stromal tumors
(GIST), Gleevec resistant GIST, advanced kidney cancers as well
as other cancers. The approval marks the first time the FDA has
approved a new oncology product for two indications simulta-
neously. Finally, a novel scaffold-based drug discovery approach
will be described that enables the development of many new fam-
ilies of inhibitors for protein kinases and other enzymes that play
a role in cell signaling.
doi:10.1016/j.ejcsup.2006.04.134
S2. Src-FROM ONCOGENE TO CLINICAL TARGET
Justin M. Summy, Michael J. Gray, Gary E. Gallick. Department of
Cancer Biology, University of Texas, M.D. Anderson Cancer Center, TX,
United States.
The protein tyrosine kinase, Src, is the founding member of a
nine-gene family that regulates such diverse processes as prolif-
eration, migration, invasion, cell survival and angiogenesis. Aber-
rantly high Src activity is seen in numerous human tumors, with
increases in Src activity associated with progressive stages of dis-
ease and poor prognosis. In mouse models for several types of
human tumors, we demonstrate that Src activation increases
metastatic potential with limited effects on primary tumor
growth. In these models, pharmacologic inhibitors of Src retard
growth of large tumors and inhibit the development of metasta-
ses. Therefore, small molecule Src-selective inhibitors are now
in clinical trial in advanced stages of a number of solid tumors.
However, given its diverse modifications, Src itself may not repre-
sent the best marker for effectiveness of these therapeutic agents.
Therefore, we have examined Src signaling pathways that pro-
mote tumor progression, with an emphasis on pro-angiogenic
pathways. Src regulates expression of vascular endothelial
growth factor (VEGF) by activating Akt, p38 and STAT3. In
addition, Src regulates IL-8 expression in a pathway requiring
